These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39136017)

  • 1. Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
    Tsujikawa T; Ohno K; Morita KI; Saburi S; Mitsuda J; Yoshimura K; Kimura A; Morimoto H; Ogi H; Shibata S; Akashi T; Kurata M; Imoto I; Shimizu Y; Kano S; Watanabe A; Yamazaki T; Asada Y; Hayashi R; Saito Y; Ozawa H; Tsukahara K; Oridate N; Sano D; Horii A; Ueki Y; Maruo T; Mukoyama N; Hanai N; Fukusumi T; Iwai H; Fujisawa T; Fujii T; Nibu KI; Iwae S; Ueda T; Chikuie N; Yasumatsu R; Matsuo M; Umeno H; Ono T; Masuda M; Toh S; Itoh K; Hirano S; Asakage T
    Front Immunol; 2024; 15():1390873. PubMed ID: 39136017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
    Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K
    Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2.
    Sato R; Komatsuda H; Inoue T; Wakisaka R; Kono M; Yamaki H; Ohara K; Kumai T; Kishibe K; Hayashi T; Takahara M
    Head Neck; 2024 Sep; 46(9):2233-2243. PubMed ID: 38665131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
    Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
    Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
    Emancipator K; Huang L; Aurora-Garg D; Bal T; Cohen EEW; Harrington K; Soulières D; Le Tourneau C; Licitra L; Burtness B; Swaby R
    Mod Pathol; 2021 Mar; 34(3):532-541. PubMed ID: 33239737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
    Okuyama K; Naruse T; Yanamoto S
    J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
    Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
    Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
    Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
    BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
    Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.
    Nishikawa D; Suzuki H; Beppu S; Terada H; Sawabe M; Kadowaki S; Sone M; Hanai N
    Cancer Sci; 2021 Jan; 112(1):339-346. PubMed ID: 33078505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.